ADDITIVE CARDIOVASCULAR RISK REDUCTION OF GLP1A AND SGLT2I IN DIABETIC PATIENTS WITH ATHEROSCLEROTIC DISEASE

被引：0
|
作者：
Loyo, Persio Lopez
Bohra, Chandrashekar
Bhatia, Kirtipal
Baruch, Lawrence
Eng, Calvin
机构：
[1] James J Peters VA Med Ctr, New York, NY USA
[2] Mt Sinai Morningside, New York, NY USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1430 / 1430
页数：1
相关论文
共 50 条
  • [21] GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
    Marx, Nikolaus
    Husain, Mansoor
    Lehrke, Michael
    Verma, Subodh
    Sattar, Naveed
    CIRCULATION, 2022, 146 (24) : 1882 - 1894
  • [22] GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region Results from the PACT-MEA studys
    Al-Dahi, Waleed A.
    Khalaf, Saeed H.
    AlRomaihi, Dalal A.
    Alamuddin, Naji M.
    Al Kandari, Hessa M.
    Abdalla, Doaa K.
    Alfadehla, Hanan Y.
    Jayyousi, Amin A.
    Siddique, Mashhood A.
    AlAlami, Usama A.
    Subbarao, Guruprasad C.
    Chetty, Shashikanth J.
    Abdulla, Jehan A.
    SAUDI MEDICAL JOURNAL, 2025, 46 (02) : 163 - 170
  • [23] SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
    Lopes, Antonio Cabral
    Lourenco, Olga
    Morgado, Manuel
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (11) : 1081 - 1088
  • [24] IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM
    Lee, Kevin
    Ikram, Mashaal
    Mishkel, Gregory J.
    Ng, Elaine
    Krupa, Edyta
    Zahvolskyy, Lidiya
    Davidson, David Jeremy
    Gordon, Robert Andrew
    Billings, Liana
    Sarav, Menaka
    Block, Romy
    Erwin, John P., III
    Qamar, Arman
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1938 - 1938
  • [25] Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications
    Blood, Alexander
    Chang, Lee-Shing
    Colling, Caitlin A.
    Gabovitch, Daniel
    Hamersky, Carol M.
    Durden, Emily
    Holt, Cassie
    Noone, Joshua
    Cannon, Christopher P.
    Wexler, Deborah J.
    Scirica, Benjamin M.
    Waterman, Fanta
    Stern, Gretchen
    Zelle, David
    DIABETES, 2022, 71
  • [26] GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease
    Morrison, Leigh
    Gabison, Jonathan
    Oshman, Lauren
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2024, 37 (03) : 372 - 382
  • [27] Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice
    Fu, Edouard L.
    Clase, Catherine M.
    Janse, Roemer J.
    Lindholm, Bengt
    Dekker, Friedo W.
    Jardine, Meg J.
    Carrero, Juan-Jesus
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 352 : 172 - 179
  • [28] Initiation of SGLT2i Versus GLP1-RA and the Risk of Chronic Kidney Disease in Persons with Type 2 Diabetes Mellitus
    Jensen, Simon K.
    Heide-Jorgensen, Uffe
    Andersen, Ina T.
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 87
  • [29] Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update
    Alam, Uazman
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 826 - 827
  • [30] PROVIDER-REPORTED BARRIERS TO GUIDELINE-DIRECTED UTILIZATION OF SGLT2I/GLP-1RA AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR DISEASE
    Qian, Frank
    Chaudhary, Richard
    Jonas, Zachary
    Ward, Charlotte
    Moran, Sara
    Quadir, Juweria
    Chen, Zsu-Zsu
    Benson, Mark D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1887 - 1887
12345